ClearPoint Neuro, Inc. CLPT shares soared 8.1% in the last trading session to close at $10. The move was backed by solid volume with far more shares changing hands than in a normal session. This ...

Deep Sail Capital, an investment management company, released its third-quarter investor letter. A copy of the letter can be downloaded here. The fund returned 5.8% net of fees in the third quarter, ...

ClearPoint Neuro is engaged with healthcare and research centers in North America, Europe, Asia, and South America. The Company is also partnered with the most innovative pharmaceutical/biotech ...

ClearPoint Neuro's business continues to perform well despite the stock struggling. The drug delivery business is thriving, which should be aided by maturing partner programs and the introduction of ...

ClearPoint's fundamentals remain strong, despite recent stock weakness. Consumables growth and an expectation of 15-20 system placements in 2025 are illustrative of this strength. The introduction of ...

ClearPoint Neuro reported total operating expenses of $11.3 million in the quarter. The company ended the period with $12.4 million in cash and cash equivalents. “Our 2025 fiscal year is off to a ...

SOLANA BEACH, CA / ACCESS Newswire / March 6, 2026 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the ...

ASPIRE-FTD Sites in the EU and U.S. to Use ClearPoint® Navigation Together With SmartFlow® Cannula for Intrathalamic Gene Therapy Administration FTD is a devastating form of early-onset dementia that ...

ClearPoint Neuro Inc. (NASDAQ:CLPT) shares are trading higher Wednesday after the company announced results from a Phase I-II clinical study evaluating its ClearPoint Prism Neuro Laser Therapy System.